Introduction {#section1-1756284818787400}
============

Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is characterized by immune-mediated injury to intrahepatic biliary epithelial cells leading to cholestasis, fibrosis, and biliary cirrhosis.^[@bibr1-1756284818787400][@bibr2-1756284818787400][@bibr3-1756284818787400]--[@bibr4-1756284818787400]^ The exact underlying etiology for this cascade of events remains unclear but is most likely multifactorial, involving genetic predisposition and exposure to environmental factors.^[@bibr5-1756284818787400]^ Current guidelines recommend 13--15 mg/kg/day ursodeoxycholic acid (UDCA) as first-line treatment for PBC.^[@bibr1-1756284818787400]^ UDCA is hepatoprotective: it has choleretic and immunomodulatory properties and stimulates biliary bicarbonate secretion.^[@bibr6-1756284818787400]^ While UDCA is very well tolerated and can ultimately improve survival free of liver transplantation,^[@bibr7-1756284818787400][@bibr8-1756284818787400][@bibr9-1756284818787400][@bibr10-1756284818787400][@bibr11-1756284818787400][@bibr12-1756284818787400][@bibr13-1756284818787400][@bibr14-1756284818787400]--[@bibr15-1756284818787400]^ approximately 40% of patients do not respond to UDCA and are at risk for progression.^[@bibr7-1756284818787400],[@bibr11-1756284818787400],[@bibr12-1756284818787400],[@bibr16-1756284818787400],[@bibr17-1756284818787400]^ Indeed, the 10-year cumulative incidence of hepatic complications among UDCA nonresponders is \>30%.^[@bibr18-1756284818787400]^ These patients must be identified early and considered for adjuvant therapies. [Figure 1](#fig1-1756284818787400){ref-type="fig"} illustrates the various classes of drugs currently under evaluation for cholestatic diseases. In 2016, obeticholic acid (OCA) received accelerated approval by the US Food and Drug Administration (FDA) for use in PBC after demonstrating beneficial effects on liver biochemistries in roughly 50% of patients with inadequate response to UDCA.^[@bibr19-1756284818787400]^ The benefits and overall effects of OCA in PBC will be described in detail in the next section. Despite the advent of UDCA and OCA, a subset of PBC patients continue to progress to end-stage liver disease and hepatocellular carcinoma.

![Novel classes of therapies for cholestatic liver diseases.\
FGF 19, fibroblast growth factor 19; FXR, farnesoid X receptor; HCO~3~, bicarbonate; *nor*UDCA, 24-*nor*ursodeoxycholic acid; PPAR, peroxisome proliferator-activated receptor.](10.1177_1756284818787400-fig1){#fig1-1756284818787400}

Primary sclerosing cholangitis (PSC) is a challenging, idiopathic cholestatic liver disease marked by chronic and progressive biliary inflammation, bile duct stricturing and fibrosis. Inflammatory bowel disease (IBD) is present in approximately two thirds of the affected population, and patients have a substantially increased lifetime risk for cholangiocarcinoma, gallbladder adenocarcinoma and colorectal cancer.^[@bibr20-1756284818787400],[@bibr21-1756284818787400]^ In contrast to PBC, the efficacy of UDCA for PSC is still uncertain and guidelines provide conflicting recommendations.^[@bibr22-1756284818787400]^ Previous studies showed biochemical improvement with UDCA 13--15 mg/kg/day, but failed to demonstrate significant benefit on important outcomes, such as death or transplant-free survival.^[@bibr23-1756284818787400],[@bibr24-1756284818787400]^ Subsequently, a randomized placebo-controlled study of 219 patients compared medium doses of UDCA (17--23 mg/kg/day) *versus* placebo for 5 years and showed a trend toward improved survival among UDCA-treated patients.^[@bibr25-1756284818787400]^ However, doses of 28--30 mg/kg/day were clearly associated with more frequent serious adverse events: patients receiving higher doses of UDCA were more likely to reach an endpoint, including cirrhosis, esophageal varices, cholangiocarcinoma, liver transplantation and death compared with those receiving placebo.^[@bibr26-1756284818787400]^ Furthermore, a subanalysis including patients with PSC and ulcerative colitis (UC) reported an increased risk of colorectal neoplasia among those receiving the high dose UDCA.^[@bibr27-1756284818787400]^ Multiple meta-analyses examining large numbers of PSC patients have also failed to show any survival benefit with UDCA.^[@bibr14-1756284818787400],[@bibr28-1756284818787400][@bibr29-1756284818787400][@bibr30-1756284818787400]--[@bibr31-1756284818787400]^ Importantly, all trials were judged to be at high risk of bias and the overall quality of evidence was very low. As of today, treatment for PSC is limited and liver transplantation is the only intervention shown to prolong survival.

Novel therapies {#section2-1756284818787400}
===============

Farnesoid X receptor agonists {#section3-1756284818787400}
-----------------------------

The farnesoid X receptor (FXR) is a nuclear hormone receptor involved in the regulation of bile acid homeostasis. FXR activation leads to downregulation of bile acid synthesis, increase in bile acid clearance, and reduction in liver and intestinal bile acid reabsorption.^[@bibr6-1756284818787400],[@bibr32-1756284818787400]^ Ligand-activated FXR binds to promoter regions on its target genes, including the short heterodimer partner (SHP), fibroblast growth factor 19 (FGF 19) and several transporters such as the bile salt export pump and organic solute transporter α/β. In turn, SHP suppresses the production of cholesterol 7-alpha-hydroxylase (CYP7A1) in the liver, the rate-determining enzyme in bile acid synthesis.^[@bibr6-1756284818787400]^ In addition to bile acid regulation, FXR plays an important role in lipid and glucose homeostasis and protects against pathogen recognition and inflammatory signaling (PAMP)-induced inflammation *via* downregulation of NF-kB pathways.^[@bibr33-1756284818787400]^ Therefore, activation of FXR results in an anti-inflammatory and anticholestatic environment that reduces exposure of the liver to toxic bile acids.^[@bibr34-1756284818787400]^ Interestingly, FXR activation has also shown antifibrotic properties in multiple animal models.^[@bibr35-1756284818787400],[@bibr36-1756284818787400]^

OCA has very strong affinity for FXR. The POISE trial randomized 216 PBC patients to receive placebo, OCA 5--10 mg (initial dose of 5 mg with ability to titrate to 10 mg if tolerated), or OCA 10 mg daily. This study demonstrated that 12 months of OCA treatment was associated with a significant improvement in alkaline phosphatase (ALP) and total bilirubin when compared with placebo, and this effect was sustained for 2 years.^[@bibr19-1756284818787400]^ The primary endpoint of the study was lowering the alkaline phosphatase to \<1.67 times the upper limit of normal, with a reduction of at least 15% from baseline, while maintaining a normal total bilirubin level. The percentage of patients that met the primary endpoint was 46% in the 5--10 mg group and 47% in the 10 mg group, as opposed to 10% in the placebo group (*p* \< 0.001 for both comparisons). Furthermore, an incremental benefit was observed with adjustment from 5 mg to 10 mg daily dosing. [Table 1](#table1-1756284818787400){ref-type="table"} summarizes findings of clinical trials with OCA and other novel therapies in cholestatic diseases.

###### 

Main findings related to the novel drugs in PBC and PSC.

![](10.1177_1756284818787400-table1)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                                   Mechanism of action                                                                                                Reference and [ClinicalTrials.gov](http://ClinicalTrials.gov) identifier   Study design                                                              Treatment duration                      Population                                 Findings
  -------------------------------------- ------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------- ------------------------------------------------------------------------- --------------------------------------- ------------------------------------------ ---------------------------------------------------------------------------------------------------------------------
  **OCA**                                FXR agonist                                                                                                        Nevens et al.^[@bibr19-1756284818787400]^\                                 RCT\                                                                      1 year                                  216 PBC with incomplete response to UDCA   In OCA-treated patients:\
                                                                                                                                                            (POISE trial)\                                                             UDCA+OCA *versus* UDCA+placebo                                                                                                                               significant improvement in ALP, total bilirubin;\
                                                                                                                                                            NCT01473524                                                                                                                                                                                                                             reduced CRP, interleukin-12, cleaved cytokeratin 18, IgA and IgG levels;\
                                                                                                                                                                                                                                                                                                                                                                                                    decrease in HDL and triglycerides;\
                                                                                                                                                                                                                                                                                                                                                                                                    increased pruritus

  **OCA**                                                                                                                                                   Kowdley et al.^[@bibr37-1756284818787400]^\                                RCT\                                                                      12 weeks                                59 PBC                                     In OCA-treated patients:\
                                                                                                                                                            NCT00570765                                                                OCA monotherapy *versus* placebo                                                                                                                             ALP reduction;\
                                                                                                                                                                                                                                                                                                                                                                                                    increased pruritus;\
                                                                                                                                                                                                                                                                                                                                                                                                    better tolerability with 10 mg/day dosing compared with 50 mg/day;\
                                                                                                                                                                                                                                                                                                                                                                                                    benefit on liver function, hepatocellular damage and cholestasis;\
                                                                                                                                                                                                                                                                                                                                                                                                    increased glutathione and osteopontin

  **OCA**                                                                                                                                                   Kowdley et al.^[@bibr37-1756284818787400]^ NCT02177136                     RCT\                                                                      24 weeks                                77 PSC                                     In OCA-treated patients:\
                                                                                                                                                                                                                                       OCA *versus* placebo                                                                                                                                         significant reduction in ALP independent of UDCA use;\
                                                                                                                                                                                                                                                                                                                                                                                                    increased pruritus

  **ATRA**                               Permissive activator of the nuclear receptor FXR/RXR                                                               Assis et al.^[@bibr39-1756284818787400]^\                                  Open-label pilot study\                                                   12 weeks                                15 PSC with incomplete response to UDCA    Reduction in ALT and C4 levels;\
                                                                                                                                                            NCT01456468                                                                ATRA+UDCA                                                                                                                                                    no significant reduction in ALP

  **NGM282**                             FGF 19 mimetic                                                                                                     Mayo et al.^[@bibr40-1756284818787400]^\                                   RCT\                                                                      28 days                                 45 PBC with pruritus                       In treatment group:\
                                                                                                                                                            NCT02026401                                                                NGM282+UDCA *versus*\                                                                                                                                        significant reduction in ALP levels;\
                                                                                                                                                                                                                                       Placebo+UDCA                                                                                                                                                 well tolerated, only minor GI side effects

  **NGM282**                                                                                                                                                Mayo et al.\                                                               RCT\                                                                      12 weeks                                62 PSC                                     In treatment group:\
                                                                                                                                                            ^[@bibr40-1756284818787400]^NCT02704364                                    NGM282 *versus* placebo                                                                                                                                      decrease in levels of serum bile acids, aminotransferases and markers of fibrosis;\
                                                                                                                                                                                                                                                                                                                                                                                                    failed to reduce ALP levels (primary endpoint)

  **Bezafibrate**                        Pan PPAR agonist                                                                                                   Corpechot et al.^[@bibr41-1756284818787400]^\                              RCT\                                                                      2 years                                 100 PBC with incomplete response to UDCA   In treatment group:\
                                                                                                                                                            (BEZURSO trial)\                                                           UDCA+\                                                                                                                                                       decreased ALP and other liver biochemistries;\
                                                                                                                                                            NCT01654731                                                                Bezafibrate\                                                                                                                                                 improvement in markers of fibrosis;\
                                                                                                                                                                                                                                       *versus* UDCA+placebo                                                                                                                                        improvement in pruritus;

  **Bezafibrate**                                                                                                                                           Reig et al.^[@bibr42-1756284818787400]^                                    Open label: bezafibrate + UDCA                                            Median treatment time 38 months         48 PBC with incomplete response to UDCA    decreased ALP and other liver biochemistries;\
                                                                                                                                                                                                                                                                                                                                                                                                    older age and lower liver stiffness score predicted response;\
                                                                                                                                                                                                                                                                                                                                                                                                    improvement in pruritus;\
                                                                                                                                                                                                                                                                                                                                                                                                    reduction in UK PBC risk score

  **Fenofibrate**                        PPARα agonist                                                                                                      Levy et al.^[@bibr43-1756284818787400]^\                                   Open label: fenofibrate + UDCA                                            48 weeks                                20 PBC with incomplete response to UDCA    Reduction in ALP, AST and IgM levels
                                                                                                                                                            NCT00575042                                                                                                                                                                                                                             

  **Fenofibrate**                                                                                                                                           Dejman et al.^[@bibr44-1756284818787400]^\                                 Open label:\                                                              6 months                                8 PSC                                      Significant reduction in ALP and ALT;\
                                                                                                                                                            NCT01142323                                                                fenofibrate                                                                                                                                                  no significant change in Mayo risk score;

  **Fenofibrate and bezafibrate**        PPARα agonists                                                                                                     Lemoinne et al.^[@bibr45-1756284818787400]^                                Open label: fenofibrate                                                   6--12 months                            15 PSC with incomplete response to UDCA    ALP, GGT and ALT decreased significantly;\
                                                                                                                                                                                                                                                                                                                                                                                                    no serious adverse events

  **Seladelpar**                         Selective PPARδ agonist                                                                                            Jones et al.^[@bibr46-1756284818787400]^\                                  RCT\                                                                      12 weeks                                41 PBC with incomplete response to UDCA    In treatment group:\
                                                                                                                                                            NCT02609048                                                                seladelpar+UDCA *versus*\                                                                                                                                    complete normalization of ALP in five patients who completed 12 weeks of therapy;\
                                                                                                                                                                                                                                       placebo+UDCA                                                                                                                                                 early termination due to significant increases in liver aminotransferases in three patients

  **Seladelpar**                                                                                                                                            Hirschfield et al.^[@bibr47-1756284818787400]^\                            RCT,\                                                                     8 weeks                                 116 PBC with incomplete response to UDCA   Interim results:\
                                                                                                                                                            NCT02955602                                                                open label,\                                                                                                                                                 reduction in ALP;\
                                                                                                                                                                                                                                       dose ranging                                                                                                                                                 no serious adverse events or transaminase elevation in an interim analysis at 12 weeks

  ***nor*UDCA**                          Sidechain-shortened derivative of UDCA                                                                             Fickert et al.^[@bibr48-1756284818787400]^\                                RCT\                                                                      12 treatment weeks + 4-week follow up   161 PSC                                    In treatment group:\
                                                                                                                                                            NCT01755507                                                                *nor*UDCA *versus* placebo                                                                                                                                   significant dose-dependent reductions in ALP levels;\
                                                                                                                                                                                                                                                                                                                                                                                                    favorable safety profile

  **Rituximab**                          Monoclonal antibody against CD20; B-cell depletion                                                                 Tsuda et al.^[@bibr49-1756284818787400]^\                                  Open label                                                                15 days                                 6 PBC with incomplete response to UDCA     Significant reduction in ALP levels;\
                                                                                                                                                            NCT00364819                                                                                                                                                                                                                             transient decreases in memory B-cell and T-cell frequencies

  **Rituximab**                                                                                                                                             Myers et al.^[@bibr50-1756284818787400]^                                   Open label                                                                6 months                                14 PBC with incomplete response to UDCA    Selective B-cell depletion, significant decrease in autoantibody production;\
                                                                                                                                                                                                                                                                                                                                                                                                    limited biochemical efficacy

  **Ustekinumab**                        Monoclonal antibody against IL-12 and IL-23                                                                        Hirschfield et al.^[@bibr51-1756284818787400]^\                            Open-label\                                                               28 weeks                                20 PBC with incomplete response to UDCA    Failed to meet primary endpoint of reduction in ALP levels;\
                                                                                                                                                            NCT01389973                                                                proof-of-concept study                                                                                                                                       no serious adverse events

  **Abatacept**                          Monoclonal antibody that targets CD80 and CD86 on antigen presenting cells and interferes with T-cell activation   Liu et al.^[@bibr52-1756284818787400]^\                                    Open label                                                                24 weeks                                19 PBC with incomplete response to UDCA    No significant changes in ALP, ALT, bilirubin, albumin, immunoglobulins, or liver stiffness;\
                                                                                                                                                            NCT02078882                                                                                                                                                                                                                             well tolerated

  **Infliximab**                         Monoclonal antibody against TNF-α                                                                                  Hommes et al.^[@bibr53-1756284818787400]^                                  RCT\                                                                      52 weeks                                24 PSC                                     In treatment group:\
                                                                                                                                                                                                                                       Infliximab *versus* placebo                                                                                                                                  failed to demonstrate efficacy: no clinical or histologic benefit

  **Simtuzumab**                         Humanized IgG4 monoclonal antibody against LOXL2                                                                   Muir et al.^[@bibr54-1756284818787400]^\                                   RCT\                                                                      96 weeks                                234 PSC                                    In treatment group:\
                                                                                                                                                            NCT01672853                                                                Simtuzumab *versus* placebo                                                                                                                                  failed to meet primary endpoint of reduction in hepatic collagen concentration;\
                                                                                                                                                                                                                                                                                                                                                                                                    no significant reduction In ALP levels;\
                                                                                                                                                                                                                                                                                                                                                                                                    well tolerated

  **Vancomycin and metronidazole**       Antibiotics;\                                                                                                      Tabibian et al.^[@bibr55-1756284818787400]^\                               RCT,\                                                                     12 weeks                                35 PSC                                     Primary endpoint of reduction in ALP levels was seen in the vancomycin groups (low-dose and high-dose vancomycin);\
                                         manipulation of gut microbiome: antimicrobial and immunomodulation effects                                         NCT01085760                                                                vancomycin (125 mg or 250 mg) *versus* metronidazole (250 mg or 500 mg)                                                                                      reduction in the PSC Mayo risk score in the low-dose vancomycin and low-dose metronidazole groups;\
                                                                                                                                                                                                                                                                                                                                                                                                    decrease in pruritus with high-dose metronidazole;\
                                                                                                                                                                                                                                                                                                                                                                                                    significant decrease in total bilirubin with low-dose metronidazole

  **Vancomycin**                         Antibiotic;\                                                                                                       Rahimpour et al.^[@bibr56-1756284818787400]^\                              RCT,\                                                                     12 weeks                                29 PSC                                     In treatment group:\
                                         manipulation of gut microbiome: antimicrobial and immunomodulation effects                                         NCT02605213                                                                vancomycin *versus* placebo                                                                                                                                  significant decrease in ALP levels and PSC Mayo Score;\
                                                                                                                                                                                                                                                                                                                                                                                                    significant decrease in symptoms: fatigue, pruritus, diarrhea and anorexia

  **Rifaximin**                          Antibiotic;\                                                                                                       Tabibian et al.^[@bibr57-1756284818787400]^\                               Open-label\                                                               12 weeks                                16 PSC                                     No significant changes in ALP, GGT, bilirubin or fatigue impact scale
                                         manipulation of gut microbiome: antimicrobial and immunomodulation effects                                         NCT01695174                                                                pilot study                                                                                                                                                  

  **Fecal microbiota transplantation**   Manipulation of gut microbiome                                                                                     NCT02424175                                                                Open-label\                                                               12 weeks                                10 PSC with IBD                            Decrease in ALP levels in post-FMT patients;\
                                                                                                                                                                                                                                       pilot study                                                                                                                                                  no adverse events
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ATRA, all-trans retinoic acid; C4, complement 4; CRP, C-reactive protein; FGF 19, fibroblast growth factor 19; FMT, fecal microbiota transplantation; FXR, farnesoid X receptor; GGT, gamma-glutamyltransferase; GI, gastrointestinal; HDL, high-density lipoprotein; IBD, inflammatory bowel disease; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; IL-12, interleukin 12; IL-23, interleukin 23; LOXL2, lysyl oxidase-like 2; *nor*UDCA, 24-*nor*ursodeoxycholic acid; OCA, obeticholic acid; PBC, primary biliary cholangitis; PPAR, peroxisome proliferator-activated receptor; PSC, primary sclerosing cholangitis; RCT, randomized clinical trial; RXR, retinoid X receptor; TNF-α, tumor necrosis factor alpha; UDCA, ursodeoxycholic acid.

In the POISE trial, serum markers of liver fibrosis did not differ significantly between the treatment groups and placebo. In addition, treatment with OCA resulted in a decrease in the high-density lipoprotein (HDL) cholesterol and triglyceride levels, and an initial mild increase in the low-density lipoprotein (LDL) cholesterol levels. Although patients with PBC typically have baseline elevation of HDL and are not at an increased risk for cardiovascular events, the long-term consequences of such OCA-induced changes in the lipid profile are yet to be determined.

Despite the demonstrated biochemical improvement, the incidence and intensity of pruritus were significantly increased in the treatment arms as compared with placebo, potentially limiting OCA use in some patients. Discontinuation rate due to pruritus was much higher in the 10 mg/day group compared with the 5--10 mg/day group, indicating that titration strategy successfully mitigated pruritus. Based on the POISE results, OCA was granted accelerated approval for treatment of PBC patients with incomplete response to UDCA or who are intolerant to UDCA. However, continued FDA approval of OCA is contingent on completion of a phase IIIb trial assessing hard clinical endpoints \[[ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT01473524\].

Use of OCA as monotherapy was also evaluated in another study comparing OCA 10 mg/day, OCA 50 mg/day and placebo in 59 patients with PBC. The study demonstrated similar biochemical effects: ALP was reduced by 53.9% and 37.2% in the OCA 10 mg and 50 mg groups, compared with 0.8% in the placebo group.^[@bibr37-1756284818787400]^ As expected, lower drug discontinuation rate and better tolerability were observed with 10 mg/day dosing compared with 50 mg/day.

After reports of hepatic decompensation, liver failure and deaths in 19 OCA-treated patients, an investigation determined that patients with Child B and C cirrhosis had been prescribed a higher than recommended dosage of OCA. As a result, in February 2018, the FDA issued a black box warning to the OCA label.^[@bibr58-1756284818787400]^ The Child-Pugh score must be calculated in patients with suspected liver cirrhosis; Child B and C patients should be started at 5 mg/week (as opposed to daily) and may be titrated up to 5 mg twice a week after 3 months if needed, and if drug is well tolerated.

To date, there is no definite evidence of improvement in long-term clinical outcomes with OCA use. However, a simulation study estimated that OCA in combination with UDCA as a second-line treatment for PBC could reduce the 15-year cumulative incidences of decompensated cirrhosis from 12.2% to 4.5%, hepatocellular carcinoma from 9.1% to 4.0%, liver transplants from 4.5% to 1.2%, and liver-related deaths from 16.2% to 5.7%.^[@bibr59-1756284818787400]^ Despite the expected substantial clinical benefit, OCA use is currently not cost effective and a significant cost reduction would be necessary to render its widespread use more feasible.^[@bibr59-1756284818787400]^

OCA is also being investigated for use in PSC. Specifically, a 24-week placebo-controlled randomized dose-ranging trial evaluated the efficacy and safety of OCA compared with placebo in 77 patients with PSC \[[ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02177136\]. Patients were randomized to one of three treatment arms: placebo, OCA 1.5--3 mg and OCA 5--10 mg, with dose titration occurring at 12 weeks. Patients receiving 1.5 mg OCA with the option to titrate to 3 mg and patients in the OCA 5--10 mg group achieved a statistically significant reduction in serum ALP as compared with placebo at week 24, with ALP decreasing by 22% in both OCA groups and increasing by 1% in the placebo group.^[@bibr38-1756284818787400]^ As was the case with PBC, pruritus was the most common adverse event, occurring in 46%, 60% and 67% of patients in the placebo, OCA 1.5--3 mg and OCA 5--10 mg groups, respectively. An open label 2-year extension phase is ongoing.

Currently, three other FXR agonists are under evaluation for PBC. These novel molecules differ from OCA by being nonsteroidal, nonbile-acid derivatives. They include: GS9674, LJN452 and EDP-305 \[[ClinicalTrials.gov](http://ClinicalTrials.gov) identifiers: NCT02943447, NCT02516605, and NCT03394924, respectively\], all undergoing phase II testing. GS9674 is also in clinical development for PSC \[[ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02943460\].

All-trans retinoic acid {#section4-1756284818787400}
-----------------------

Another potential target to treat cholestasis is the retinoid X receptor (RXR), a heterodimer of FXR. All-trans retinoic acid (ATRA) is a permissive activator of the nuclear receptor FXR/RXR and several *in vitro* and animal models have demonstrated treatment with ATRA decreased hepatic inflammation, fibrosis, bile duct proliferation, and bile acid pool size. Interestingly, a recent pilot study of ATRA combined with moderate-dose UDCA was performed in PSC patients and showed improvement in ALT and complement-4 levels, but unfortunately its effect on ALP did not reach statistical significance.^[@bibr39-1756284818787400]^

Fibroblast growth factor 19 mimetics {#section5-1756284818787400}
------------------------------------

As mentioned, one of the many downstream effects of FXR activation is increased gene transcription of FGF 19, an enteral hormone known to repress bile acid synthesis *via* downregulation of CYP7A1.^[@bibr1-1756284818787400],[@bibr34-1756284818787400]^ FGF 19's anticholestatic benefit may be limited by its proproliferative and procarcinogenic properties, which in mouse models have been implicated in the development of hepatocellular carcinoma.^[@bibr32-1756284818787400]^ However, new molecules were developed with alterations to FGF 19's amino acid sequence that may limit its procarcinogenic properties and promote its anticholestatic effect.^[@bibr32-1756284818787400]^ NGM282 is one such nontumorigenic FGF 19 derivative. In a phase II multicenter, randomized, double-blinded, placebo-controlled trial enrolling 45 patients with PBC who were inadequate responders to UDCA, NGM282 was administered as a daily subcutaneous injection of 0.3 mg or 3 mg *versus* placebo for 28 days.^[@bibr40-1756284818787400]^ Treated patients showed statistically significant reductions in ALP levels and other liver biochemistries. NGM282 was safe and well tolerated, with only mild adverse events reported, including diarrhea, nausea and headache.

NGM282 was also evaluated in a phase II trial for PSC \[[ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02704364\]. Although results were not published, a press release statement from NGM Bio reported that NGM282 did not meet the primary study endpoint of lowering serum ALP (<http://www.ngmbio.com/media/press-releases/020518/>). However, the drug did reduce levels of serum bile acids, aminotransferases and markers of fibrosis; it is unclear whether it will be examined further in PSC.

Peroxisome proliferator-activated receptor agonists {#section6-1756284818787400}
---------------------------------------------------

Another key player in the regulation of bile acid homeostasis is the peroxisome proliferator-activated receptor, specifically the alpha and delta isoforms (PPARα, PPARδ).^[@bibr1-1756284818787400],[@bibr6-1756284818787400]^ PPARα acts on nuclear transcription factors to reduce inflammation and promote bile acid excretion through stimulation of multidrug resistance protein 3.^[@bibr34-1756284818787400]^ Fibrates are the most well-known class of drug to activate PPARα.^[@bibr6-1756284818787400]^ While published clinical trials examining fibrates in PBC are small, most patients had a significant biochemical response.^[@bibr43-1756284818787400],[@bibr60-1756284818787400][@bibr61-1756284818787400][@bibr62-1756284818787400][@bibr63-1756284818787400][@bibr64-1756284818787400][@bibr65-1756284818787400]--[@bibr66-1756284818787400]^ Of significance, a large randomized controlled trial including 100 patients with PBC treated for 2 years with either UDCA/placebo or UDCA/bezafibrate (the BEZURSO trial) was presented at the International Liver Congress in 2017. Combination therapy with bezafibrate was associated with marked biochemical improvement, including 67% of patients normalizing their ALP and 30% normalizing all liver biochemistries, improvement in markers of fibrosis, and also symptomatic improvement in pruritus.^[@bibr41-1756284818787400]^Similarly, an open-label study of 48 PBC patients treated with combination therapy of UDCA (13--16 mg/kg/day) and bezafibrate (400 mg/day) demonstrated an ALP decrease in all patients and normalization in 54%. Older patients with milder amounts of fibrosis (liver stiffness scores \< 7.3 kPa) were more likely to normalize ALP. In addition, the study showed marked relief in pruritus among treated patients.^[@bibr42-1756284818787400]^ A meta-analysis on bezafibrate for PBC confirmed that the addition of bezafibrate improves liver biochemistries and can potentially improve prognosis, given the significant reduction in the Mayo risk score.^[@bibr67-1756284818787400]^ With the caveat that the meta-analysis was conducted prior to publication of the French and Spanish studies, it did not show a benefit on survival rate or pruritus.

In the US, an open-label study of 20 patients with PBC who had incomplete response to UDCA showed that combination therapy of UDCA and fenofibrate for 48 weeks led to a ⩾40% reduction in ALP in 55% of study subjects.^[@bibr43-1756284818787400]^ A recent meta-analysis of six studies of fenofibrate for PBC, including a total of 102 patients, found that 69% of patients with no or incomplete response to UDCA achieved a complete response when fenofibrate (100--200 mg/day) was added.^[@bibr68-1756284818787400]^ Pooled analysis showed that use of fenofibrate led to a significant decrease in ALP, gamma-glutamyltransferase (GGT), total bilirubin and immunoglobulin M levels.

Adverse events associated with fibrates include myalgias, arthritis, leg edema, polydipsia, hepatotoxicity and gastrointestinal upset (especially esophageal reflux and nausea).^[@bibr43-1756284818787400],[@bibr67-1756284818787400]^ Studies have reported elevations of serum creatinine phosphokinase and serum creatinine levels, which should be monitored especially with long-term use, although a significant reduction in glomerular filtration rate has not been observed.^[@bibr62-1756284818787400],[@bibr69-1756284818787400]^

The selective PPARδ agonist seladelpar was recently investigated in a 12-week randomized controlled trial of patients who did not respond adequately to UDCA. Seladelpar was associated with significant increases in liver aminotransferases in three patients and therefore the study was terminated early. Despite the early termination, however, all five patients who completed the 12 weeks of treatment with seladelpar had complete normalization of ALP.^[@bibr46-1756284818787400]^ As a result, an open-label study was initiated evaluating lower doses of 5 mg/day and 10 mg/day for 26 weeks \[[ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02955602\]. Planned interim analysis conducted at 12 weeks demonstrated no safety concerns. ALP normalized in 18% and 45% of patients on 5 mg/day and 10 mg/day, respectively.^[@bibr47-1756284818787400]^ As a result, an even lower dose of 2 mg/day is currently under evaluation.

Elafibranor is a potent PPARα, δ agonist and is currently undergoing investigation in a phase II clinical trial involving 45 patients with PBC \[[ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT03124108\]. Another dual PPARα and γ agonist, saroglitazar, is under investigation in a phase II study examining its safety, tolerability and efficacy in treating PBC \[[ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT03112681\].

PPAR agonists have also been investigated for their potential usefulness in PSC, albeit only in a couple of small studies. Collective experience from a total of 25 patients treated with bezafibrate^[@bibr70-1756284818787400],[@bibr71-1756284818787400]^ and 21 patients treated with fenofibrate^[@bibr44-1756284818787400],[@bibr45-1756284818787400]^ for 3--12 months indicate that use of fibrates can lead to significant improvement of ALP, GGT and ALT. In addition, a systematic analysis including the 25 Japanese patients suggests that preserved liver function may predict biochemical response to bezafibrate.^[@bibr72-1756284818787400]^

24-*nor*ursodeoxycholic acid {#section7-1756284818787400}
----------------------------

One of the many scientific breakthroughs for understanding cholestasis stems from a belief that a hydrophilic environment combined with the production of bicarbonate protects cholangiocytes and hepatocytes from bile acid toxicity.^[@bibr6-1756284818787400]^ *nor*UDCA (24-*nor*ursodeoxycholic acid) is a novel agent that lacks a methylene group compared with its relative, UDCA.^[@bibr73-1756284818787400]^ This missing methylene group allows *nor*UDCA to be passively absorbed from cholangiocytes, through a process termed 'cholehepatic shunting.'^[@bibr6-1756284818787400]^ This results in the production of bicarbonate, creating a more hydrophilic and less toxic environment to hepatocytes and cholangiocytes.^[@bibr74-1756284818787400][@bibr75-1756284818787400]--[@bibr76-1756284818787400]^ Experimental mouse models of cholangiopathies have shown promising results when treated with *nor*UDCA, which demonstrated antiproliferative, antifibrotic and anti-inflammatory properties.^[@bibr77-1756284818787400][@bibr78-1756284818787400][@bibr79-1756284818787400]--[@bibr80-1756284818787400]^ A recent phase II clinical trial of 159 PSC patients randomized to various doses of *nor*UDCA *versus* placebo demonstrated statistically significant dose-dependent reductions in ALP levels in treated patients compared with placebo as well as a favorable safety profile.^[@bibr48-1756284818787400]^ Such biochemical response was independent of prior response to UDCA and of disease stage. Therefore, use of *nor*UDCA may play a significant role in the treatment of cholestasis. It is possible that *nor*UDCA would have synergistic effects with UDCA, although this remains to be examined. A larger phase III study expected to enroll 300 patients with PSC is ongoing in Europe to further evaluate the safety and efficacy of *nor*UDCA \[EudraCT no.: 2016-003367-19\].

Immunomodulatory treatments {#section8-1756284818787400}
---------------------------

The PBC liver is infiltrated with both T and B cells, leading to mass production of cytokines and chemokines that ultimately play a role in the pathogenesis of the disease.^[@bibr81-1756284818787400],[@bibr82-1756284818787400]^ Rituximab, a monoclonal antibody targeting the CD20 antigen on the B cell, is used in a wide array of diseases including IBD, rheumatologic diseases, and various hematologic malignancies. Rituximab has been investigated for potential benefits in PBC as well. In one open-label study, six PBC patients with inadequate response to UDCA were treated with rituximab infusions and showed improvement in ALP levels. However, in another open-label study of 14 PBC patients, reductions in liver biochemistries were not as pronounced despite improvement in pruritus.^[@bibr49-1756284818787400],[@bibr50-1756284818787400]^ Of interest, a phase II trial of rituximab *versus* placebo is underway for 78 PBC patients with complaints of fatigue to examine the potential benefit on these patients' quality of life.^[@bibr83-1756284818787400]^ As of today, the evidence for rituximab's efficacy in treating PBC is insufficient. Results of the RITPBC trial for fatigue are awaited.

Increased expression of interleukin 23 (IL-23) was observed in peripheral blood cells of patients with PBC, and IL-23 levels correlated with clinical disease stages.^[@bibr51-1756284818787400],[@bibr84-1756284818787400][@bibr85-1756284818787400]--[@bibr86-1756284818787400]^ Furthermore, genes associated with the production of IL-12 were upregulated in genome-wide association studies and have been implicated in the pathogenesis of PBC.^[@bibr51-1756284818787400],[@bibr87-1756284818787400]^ For these reasons, ustekinumab, a monoclonal antibody against IL-12 and IL-23, was examined in PBC patients who did not respond to UDCA; however, it failed to meet the primary endpoint of improvement in serum ALP after 28 weeks of therapy.^[@bibr1-1756284818787400],[@bibr51-1756284818787400]^ The study has been criticized for enrolling patients with more advanced disease stages, which may not be expected to respond well to immunomodulatory therapies.

Abatacept is a monoclonal antibody that targets CD80 and CD86 on antigen-presenting cells and interferes with T-cell activation. As was the case with ustekinumab, abatacept also failed to meet the primary endpoint in a small study for PBC.^[@bibr52-1756284818787400]^

Evaluating the role of immunomodulatory therapy in cholestatic liver diseases is a challenging undertaking. The timing of therapy initiation is a major issue, as it is expected that patients in earlier disease stages are more likely to benefit from immunomodulation. However, currently, patients are selected for clinical trial participation based on nonresponse to UDCA, thus in a more advanced cholestatic phase already beyond that initial immune attack. Identifying patients at the very early disease stages is difficult and it is likely that we would need combination therapy targeting different disease processes at the same time, using, for instance, immunomodulatory drugs combined with anticholestatic agents. Furthermore, the appropriate study endpoint may not be serum levels of ALP, which is the marker of cholestasis currently used as primary endpoint in most clinical trials, and may involve obtaining serial liver biopsies for immunohistochemistry testing.

Immunomodulatory therapy has also been investigated in patients with PSC. Infliximab, a monoclonal antibody against tumor necrosis factor-α, used commonly in IBD, was investigated in a small number of PSC patients, without any clinical or histological benefit.^[@bibr53-1756284818787400]^ Other trials have examined the effects of methotrexate, mycophenolate mofetil, and etanercept, with no efficacy observed.^[@bibr88-1756284818787400][@bibr89-1756284818787400]--[@bibr90-1756284818787400]^

Antifibrotic therapies {#section9-1756284818787400}
----------------------

Fibrosis in PBC is believed to stem from T-cell-mediated damage and cholestasis-induced injury to biliary epithelial cells, with release of fibrogenic mediators that activate neighboring fibroblasts to secrete collagen, including transforming growth factor β1, platelet-derived growth factor BB and endothelin-1.^[@bibr73-1756284818787400],[@bibr91-1756284818787400]^ In animal models, the FXR agonist OCA also has antifibrotic properties.^[@bibr92-1756284818787400][@bibr93-1756284818787400]--[@bibr94-1756284818787400]^ While this has not yet been demonstrated in humans, the fact that OCA-treated patients in the POISE trial had improvement in the AST/platelet ratio index (APRI) scores hints at this possibility. Future studies looking at changes in liver stiffness, enhanced liver fibrosis scores and the APRI score will clarify this issue.

Of interest is the role of the vitamin D receptor (VDR) as the downward effects of this receptor are implicated in interfering with T-cell immune response.^[@bibr6-1756284818787400]^ Not only have VDR agonists shown playing a role in bile acid detoxification but, in mouse models, they have also demonstrated the ability to modulate fibrogenesis.^[@bibr6-1756284818787400]^ For these reasons, the VDR and its ligands are of interest in the treatment of fibrosis and further investigation in human trials is needed.

Other cellular targets are under investigation for their role in preventing fibrosis or inducing its regression, such as lysyl oxidase-like 2 (LOXL2). Simtuzumab is a monoclonal antibody directed against LOXL-2 which was evaluated in a 2-year study including 234 PSC patients \[[ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT01672853\]. Unfortunately, use of simtuzumab was not associated with a reduction in hepatic collagen concentration.^[@bibr54-1756284818787400]^

Manipulation of gut microbiome {#section10-1756284818787400}
------------------------------

The gut microbiome plays an important role in the regulation of both innate and adaptive immune systems through the gut--liver--immune-system axis. The gut microbiome composition is altered in several chronic liver diseases and has been implicated in the pathogenesis of alcoholic and nonalcoholic fatty liver disease, as well as in PBC and PSC. This dysbiosis generates an imbalance in production of cytoprotective *versus* injurious metabolites and may lead to abnormal immunological development. Important abnormalities may result, such as an increase in lipopolysaccharide in the portal circulation, a decrease in seven alpha-dehydroxylation by gut bacteria, and a subsequent accumulation of primary bile acids that leads to stimulation of FXR and downregulation of CYP7A1 in the liver.^[@bibr55-1756284818787400],[@bibr95-1756284818787400]^ As a result, a bile-acid--intestinal-microbiota--cholestasis triangle has been postulated in the pathogenesis of PBC and PSC, suggesting a multidirectional interaction of these factors. Bile acids can modulate the gut microbiota by decreasing the pool of some bile-sensitive bacteria and facilitating proliferation of other species. Conversely, the microbiome can shape the bile acid pool and bile acid receptors. This disturbance in bile acid metabolism leads to the development and progression of cholestasis, which can further alter gut microbiota and exacerbate cholestasis in this interactive cycle.^[@bibr96-1756284818787400]^

Gut dysbiosis and reduced bacterial diversity is consistently found in patients with PSC.^[@bibr95-1756284818787400]^ Kummen and colleagues found that patients with PSC had a gut microbial signature distinct from both healthy controls and patients with UC without liver disease.^[@bibr97-1756284818787400]^ Interestingly, the microbiota of PSC patients with and without IBD was similar, however PSC-IBD patients were noted to have decreased diversity compared with patients with UC without biliary disease, and healthy controls. Over-representation of the *Veillonella* genus was noted only in PSC patients and, interestingly, enrichment with *Veillonella* has been linked to increased rates of fibrosis, not only in PSC but also in other fibrosing diseases such as idiopathic pulmonary fibrosis. Therefore, manipulation of the microbiota *via* antimicrobials, probiotics, or fecal microbiota transplantation (FMT) might offer new therapeutic options.

Several antibiotics have been examined in PSC, including vancomycin, metronidazole, minocycline, tetracycline and rifaximin.^[@bibr98-1756284818787400][@bibr99-1756284818787400][@bibr100-1756284818787400]--[@bibr101-1756284818787400]^ Despite modest improvements in liver biochemistries with most antimicrobials, evidence for long-term clinical benefit is lacking. Vancomycin is the most studied antibiotic and its use has been extensively reviewed.^[@bibr102-1756284818787400]^ Vancomycin use is consistently associated with a significant decline in ALP levels and PSC Mayo risk score.^[@bibr55-1756284818787400],[@bibr56-1756284818787400]^ Interestingly, a trial that studied different dosing options for vancomycin and metronidazole demonstrated a significant decrease in total bilirubin levels with low-dose metronidazole and a decrease in pruritus with the high-dose metronidazole, but without improvement in ALP; only vancomycin met the primary endpoint of reduction in ALP.^[@bibr55-1756284818787400]^ A phase III study is now being conducted to assess the benefit of oral vancomycin for PSC in IBD patients \[[ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT01802073\]. In contrast, an open-label pilot study of oral rifaximin did not show significant changes in ALP levels and seemed inefficacious for the treatment of PSC.^[@bibr57-1756284818787400]^

Altering the gut microbiota without using pharmacological drugs is another promising approach. This can be achieved with probiotics and FMT. An open-label pilot study is evaluating the microbiological and clinical effects of FMT in 10 patients with PSC. Preliminary results showed that post-FMT patients had a ⩾50% decrease in ALP by week 26 and no adverse events were observed \[[ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02424175\]. On the other hand, probiotics were studied in a crossover study of PSC patients with IBD, and no beneficial effects were demonstrated on biochemistries.^[@bibr103-1756284818787400]^ The use of various microbiome-altering modalities may play a role in the treatment of PSC, but further trials are needed.

Conclusion {#section11-1756284818787400}
==========

New promising targets for the treatment of cholestatic liver diseases have emerged, with the recent advances in the knowledge of molecular mechanisms implicated in these diseases. FXR agonists represent an interesting option for treating cholestasis, with established benefits in PBC and possibly in PSC. Fibrates have been associated with significant biochemical improvement and have the added benefit of ameliorating pruritus. Fibrates appear to have greater efficacy in patients with lower fibrosis scores. Early identification of PBC patients who are nonresponders to UDCA and candidates for adjuvant therapy is paramount. Innovative treatments for PSC include *nor*UDCA and microbiome-related therapies such as vancomycin and FMT. *nor*UDCA in particular has antifibrotic, anticholestatic and anti-inflammatory properties and results of the proof-of-concept study were very encouraging. Furthermore, combination therapy affecting multiple pharmacologic targets with different mechanisms of action is an attractive approach for both PBC and PSC.
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